Related Experiment Video
Updated: Feb 16, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Accelerated approval of medicines: fit for purpose?
Alasdair Breckenridge1, Lawrence Liberti2
1Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3BX, UK.
Abstract:
The uptake of a new medicine represents a balance between benefit-risk assessment and value considerations. In the case of products approved via accelerated pathways, the increased uncertainty adds to the challenge. Here, we suggest solutions so that regulators, companies, payers and patients can align around management of the uncertainties and expectations.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Purposive Learning
Inclusive Fitness
Goodness-of-Fit Test
Accelerators
The effectiveness of calcium chloride can...

